We sought to develop criteria for ERBB2-positivity (HER2) in colorectal cancer to ensure accurate identification of ERBB2-amplified metastatic colorectal cancer patients suitable for enrolment in a phase II trial of ERBB2-targeted therapy (HERACLES trial). A two-step approach was used. In step 1, a consensus panel of pathologists adapted existing protocols for use in colorectal cancer to test ERBB2 expression and amplification. Collegial revision of an archival test cohort of colorectal cancer samples led to specific recommendations for adapting current breast and gastric cancer criteria for scoring ERBB2 in colorectal cancer. In step 2, from September 2012 to January 2015, colorectal-specific ERBB2 testing protocols and ERBB2 scoring criteria were used to centrally screen for ERBB2-positive KRAS wild-type colorectal cancer patients to be enrolled in the HERACLES trial (clinical validation cohort). In both archival test (N = 256) and clinical validation (N = 830) cohorts, a clinically sizeable 5% fraction of KRAS wild-type colorectal cancer patients was found to be ERBB2-positive according to the colorectal cancer-specific ERBB2 scoring criteria. ERBB2-positive tumors showed ERBB2 immunostaining consisting of intense membranous ERBB2 protein expression, corresponding to homogenous ERBB2 amplification, in 450% of cells. None of the immunohistochemistry 0 or 1+ cases was amplified. Concordance between SISH and FISH was 100%. In conclusion, we propose specific criteria for defining ERBB2-positivity in colorectal cancer (HERACLES Diagnostic Criteria). In a phase II trial of trastuzumab and lapatinib in a cetuximabresistant population, HERACLES Diagnostic Criteria shaped the selection of patients and defined ERBB2 as a predictive marker for response to ERBB2-targeted therapy in metastatic colorectal cancer.
We sought to develop criteria for ERBB2-positivity (HER2) in colorectal cancer to ensure accurate identification of ERBB2-amplified metastatic colorectal cancer patients suitable for enrolment in a phase II trial of ERBB2-targeted therapy (HERACLES trial). A two-step approach was used. In step 1, a consensus panel of pathologists adapted existing protocols for use in colorectal cancer to test ERBB2 expression and amplification. Collegial revision of an archival test cohort of colorectal cancer samples led to specific recommendations for adapting current breast and gastric cancer criteria for scoring ERBB2 in colorectal cancer. In step 2, from September 2012 to January 2015, colorectal-specific ERBB2 testing protocols and ERBB2 scoring criteria were used to centrally screen for ERBB2-positive KRAS wild-type colorectal cancer patients to be enrolled in the HERACLES trial (clinical validation cohort). In both archival test (N = 256) and clinical validation (N = 830) cohorts, a clinically sizeable 5% fraction of KRAS wild-type colorectal cancer patients was found to be ERBB2-positive according to the colorectal cancer-specific ERBB2 scoring criteria. ERBB2-positive tumors showed ERBB2 immunostaining consisting of intense membranous ERBB2 protein expression, corresponding to homogenous ERBB2 amplification, in 450% of cells. None of the immunohistochemistry 0 or 1+ cases was amplified. Concordance between SISH and FISH was 100%. In conclusion, we propose specific criteria for defining ERBB2-positivity in colorectal cancer (HERACLES Diagnostic Criteria). In a phase II trial of trastuzumab and lapatinib in a cetuximabresistant population, HERACLES Diagnostic Criteria shaped the selection of patients and defined ERBB2 as a predictive marker for response to ERBB2-targeted therapy in metastatic colorectal cancer. The human epidermal growth factor receptor 2 gene ERBB2 (HER2) is amplified and its protein is overexpressed in many cancer types. 1, 2 Overexpression of ERBB2 is an established therapeutic target in breast and gastric cancers and is successfully exploited in the clinic using a variety of anti-ERBB2 agents, leading to remarkable outcome improvements. 3, 4 Although the comprehensive molecular characterization of human colorectal cancer has identified ERBB2 amplification as a potential therapeutic target 5 and ERBB2 overexpression has been controversially linked to prognosis, [6] [7] [8] [9] the clinical significance of ERBB2 alterations remains elusive. Recently, we and others have found that activation of ERBB2 signaling causes resistance to anti-EGFR therapy in a fraction of metastatic colorectal patients, wild type for RAS codons 12-13. [10] [11] [12] Of more relevance for the clinic, we have demonstrated that the combination of the anti-ERBB2 monoclonal antibody trastuzumab and the dual EGFR/HER2 small-molecule inhibitor lapatinib, but not either drug alone, is effective in inducing durable tumor shrinkage in ERBB2-amplified metastatic CRC patient-derived xenografts. 10 Reasoning that ERBB2 corsivo could also represent a valuable therapeutic target in KRAS wild-type metastatic colorectal cancer patients resistant to anti-EGFR treatment, we designed the HERACLES trial, a phase II trial testing the combination of trastuzumab and lapatinib in ERBB2-positive metastatic colorectal cancer patients refractory to standard treatment, including cetuximab or panitumumab. 11 Prior to starting the HERACLES trial, we elected to develop colorectal cancer-specific criteria for the definition of ERBB2 positivity. Immunohistochemistry and fluorescent or silver in situ hybridization (FISH or SISH) are current standard methodologies to detect respectively ERBB2 protein expression and gene amplification on formalin-fixed paraffin-embedded tumor samples. These are routinely used to establish ERBB2 status in breast and gastric cancer but have not been customized for colorectal cancer for which the reported rate for ERBB2 positivity ranges enormously from o1% to 450%. [6] [7] [8] [9] [12] [13] [14] [15] [16] [17] [18] [19] [20] The aim of the present study was to develop a validated ERBB2 scoring system for colorectal cancer with the goal of identifying ERBB2-positive patients suitable for enrollment in the HERACLES trial.
Materials and methods

Study Design
This was a two-steps study.
Step 1 was conducted on formalin-fixed paraffin-embedded archival samples (archival test cohort). A consensus panel of three pathologists (i) defined, by similarity with breast and gastric cancers, the technical protocols of assessment for two immunohistochemistry staining protocols and two in situ hybridization methods; (ii) appointed one member of the consensus panel (MG) to review all samples; (iii) established the criteria by which samples for collegial review were to be selected by the appointed pathologist for consensus revision; (iv) collegially read and discussed the characteristics of the selected samples during a day-long consensus session, and (v) as a result of the consensus review formulated a diagnostic algorithm for ERBB2 positivity in colorectal cancer, referred to as HERACLES Diagnostic Criteria.
Step 2 was conducted on samples from KRAS 12/13 wild-type metastatic colorectal cancer patients prospectively screened for the HERA-CLES trial (clinical validation cohort). A centralized pathology laboratory (Niguarda Cancer Center, Milan, Italy) processed all samples, including those already tested for ERBB2 at HERACLES participating centers. The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice. Informed consent, allowing the use of the patient's surgical/bioptical specimen for diagnostic purposes, was available for each archival sample of the archival test cohort, while for the screening (clinical validation cohort), patients signed a protocol-specific informed consent approved by independent Ethical Committees.
ERBB2 Status
ERBB2 expression analysis by immunohistochemistry was performed manually using HercepTest antibody (Dako A/S Glostrup, Denmark) and automatically on the automated Bench Mark Ultrasystem using the VENTANA 4B5 antibody, following the manufacturers' instructions in both cases.
ERBB2 amplification analysis by FISH was performed with a PathVysion HER-2 DNA Probe Kit (Abbott Laboratories, Des Plaines, IL, USA) and SISH with a VENTANA 4B5 Inform HER2 dual-color on the BenchMark Ultra system (Inform HER2 DNA dualcolor assay-Roche Tissue Diagnostics, VENTANA Medical Systems, SA). The scoring and evaluation for in situ hybridization was performed by counting ERBB2 and CEN17 signals from 100 nuclei per case. Non-tumor tissue (normal colon mucosa) was used as an internal negative control. Samples with a ERBB2/ CEN17 ratio ≥ 2.0 were considered amplified. Images were captured with the Axiovision software using an Axio Zeiss Imager 2 microscope for IHC and SISH and the ISIS Metasystems software using an Axio Zeiss Imager Z1 microscope for FISH.
Analysis
A sample was considered evaluable for review when all test results were present. At least one evaluable sample was required to consider a patient evaluable. In the case of multiple samples, the highest immunohistochemistry value defined the patient score. In step 1, scoring procedures for immunohistochemistry and in situ hybridization took into account the standard scoring systems for breast and gastric cancers. [21] [22] [23] In the first analysis, three staining parameters, ie, pattern of membranous reactivity, intensity of reactivity, and percentage of immunoreactive cells, were combined as shown in Figure 1a . Only samples with a ratio ERBB2: CEN17 ≥ 2 or staining equivocal (2+) or positive (3+) in at least 10% of cells were selected for review, together with a small set of samples scoring immunohistochemistry 0/1+ as negative controls. In step 2, only the VENTANA 4B5 and FISH kits were used for ERBB2 determination. All samples were centrally scored according to HERACLES Diagnostic Criteria.
We used percentage and mean for qualitative variables and s.d. for quantitative variables. Receiver operating characteristic (ROC) curves were used to determine test performances for each IHC method; accuracy, sensitivity, specificity, and positive and negative predictive values, were calculated in the two series using in situ hybridization as the gold standard and a cutoff for immunohistochemistry positivity as defined by the HERACLES Diagnostic Criteria.
Results
Archival Test Cohort (Step 1)
The characteristics of the 359 patients with colorectal adenocarcinoma who provided 482 tumor samples for the archival test cohort and the Study Consort are reported in Supplementary Figures S1A and B. Of the 482 samples, 66 (14%, derived from 49 patients) were from KRAS exon 2 mutated cancers. Overall, 134 samples (22 KRAS mutated) could not be assessed with all planned procedures because of insufficient tumor material (N = 36, 27%), initial technical problems with the first SISH method used (INFORM HER2-VENTANA, N = 94, 70%) and sub-optimal tissue preparation (N = 4, 3%), leaving 348 evaluable samples (44 KRAS mutated) (Supplementary Figure  S1B) . Fifty-eight percent of the evaluable KRAS wildtype samples were from primary cancers, 13% from metastatic sites, and 29% from both primary and metastatic sites (Supplementary Figures S1C and D) .
Immunohistochemistry and SISH results are reported in Table 1 . Of the 44 KRAS mutated samples (Table 1A) , none was ERBB2 amplified or expression positive (3+). Equivocal (2+) staining was observed in six samples with VENTANA 4B5 and one sample with HercepTest, leaving 97% HercepTest and 86% VEN-TANA 4B5 negative samples. In KRAS wild-type samples (Table 1B) , immunohistochemistry positivity (3+) with strong circumferential membrane immunostaining was observed in 14 cases (4.6%) with HercepTest and 16 cases (5.3%) with VENTANA 4B5. Equivocal staining (2+) with weak-to-moderate circumferential basolateral or lateral immunoreactivity was seen in 410% of cells and was more frequent with VENTANA 4B5 (N = 23, 7.6%) than with HercepTest (N = 3, 1%). VENTANA 4B5 did not stain (0) or faintly stained (1+) 87% of samples (0, N = 170, 1+, N = 95; total N = 265); none of these samples was amplified by SISH. HercepTest stained negative (0) in 74% of samples (N = 226), including one SISH-positive sample (staining 3+ with VENTANA 4B5) and faintly stained (1+) the remaining 61 samples (20%), none of which was amplified. The comparative analysis between immunohistochemistry and SISH results, used as the 'gold standard', is also reported in Table 1 . Overall, ERBB2 amplification in KRAS wild-type cases was observed in 17 samples (5.6% of samples, corresponding to 5.1% of patients), and of these 16 (94.1%) scored positive (3+) and 1 equivocal (2+) with VENTANA 4B5. With HercepTest, 14 (82.4%) were positive (3+), 2 equivocal (2+) and 1 negative (0).
Concordance between samples from primary and metastatic tumor sites in the same patients was possible for 95 paired samples from 47 patients (1 patient had two metastatic site samples, Supplementary Table S1 ). There were four ERBB2 amplified cases (8.5%): VENTANA 4B5 stained all four paired samples positive (3+), while HercepTest only three of the pairs. The remaining amplified case scored equivocal (2+) in the primary and predominantly negative (0) in the paired liver metastasis. This latter case, however, was also the only one showing clear intra-sample heterogeneity out of the 17 ERBB2-amplified cases, with areas of strong 3+ reactivity to VENTANA 4B5 coexisting with areas of no (0) or faint reactivity (1+) corresponding to ERBB2-amplified and non-amplified tumor areas, respectively, in both the primary and the metastatic tumors ( Figure 2 ).
Consensus Panel of Pathologists Review
The Consensus Panel of Pathologists reviewed only cases that were informative for all three analyses. (Figures 3a and b) . With VENTANA 4B5, 93% (N = 13) of the 14 amplified samples scored immunohistochemistry positive in ≥ 50% of cells, mostly clustering at or above the 90% cellularity mark, while non-amplified positive (3+) or equivocal samples (2+) clustered below the 30% cellularity mark. Interestingly, the only sample with less than a 50% cellularity score was the sample with high intra-sample heterogeneity shown in Figure 2 . In contrast, HercepTest-positive Figure 1b . At the end of the review process, the Consensus Panel of Pathologists formulated a set of specific criteria for determining ERBB2 positivity in colorectal cancer, referred to as HERACLES Diagnostic Criteria. The assessment of ERBB2 positivity in colorectal cancer according to these criteria is a two-tier process whereby locally assessed samples, if negative (0/1+) or equivocal (2+) in o50% of cells, are excluded from further testing, while centralized immunohistochemistry and in situ hybridization re-testing is carried out according to specific staining intensities and cellularity cutoffs as reported in Table 3 .
Clinical Validation Cohort (Step 2)
We screened 830 KRAS wild-type colorectal cancer patients according to HERACLES Diagnostic Criteria. ERBB2 overexpression (2+/3+) and amplification prevalence rates are reported in Table 4 together with the summarized archival results for comparison. The prevalence of overexpressed cases significantly decreased from the archival to the screening cohort, from 13.7 to 8.4%, respectively (P = 0.02).
On the contrary in both series the prevalence of confirmed ERBB2 amplification was 5% (5.1 vs 5.2%). Interestingly all immunohistochemistry positive (3+) cases were amplified in both cohorts, while the percentage of amplified equivocal (2+) tumors increased from 4.3 to 27% from the archival to the screening cohort, respectively. VENTANA 4B5 test performances in the screening compared with the archival data sets using the ≥ 50% cellularity cutoff were identical for accuracy (96.7%), sensitivity (100%), and negative predictive value (100%). Specificity was higher in the screening data set than in the test data set (96.6 vs 94.1%, respectively), while, inversely, the positive predictive value decreased from 93 to 61% (Supplementary Table S2 ).
Discussion
While exploring ERBB2 as an actionable therapeutic target in colorectal cancer in the HERACLES trial, by assessing the activity of dual ERBB2 inhibition with trastuzumab and lapatinib, we investigated the prevalence of ERBB2 overexpression and amplification in more than a thousand prevalently metastatic colorectal cancer patients. The aim of the study was threefold.
First, a panel of ERBB2 expert pathologists established that breast and gastric criteria for ERBB2 positivity determination could also be made suitable to score ERBB2 accurately and reproducibly in colorectal cancer. Technically, the Consensus of Pathologists Panel selected VENTANA 4B5 over HercepTest for protein expression determination because of lack of false negatives with the former. On the other hand, VENTANA 4B5, which recognizes both ERBB2 and ERBB4, had a higher false positive rate than the HercepTest, which uses a ERBB2-specific polyclonal antibody. This could be related to a cross-reaction of VENTANA 4B5 to ERBB4, or to operator-dependent factors resulting from the stronger retrieval processing procedure and the darker chromogen of the method. Given the relatively low prevalence of ERBB2-positive cases in colorectal cancer, the panel chose sensitivity over specificity to maximize potential ERBB2-positive patient's identification. The panel, recognizing that SISH analysis is more adaptable to processing of large sample batches (as in the archival collection) while FISH is more suitable for one-by-one screening, and because of the nearly perfect concordance between these two methods, also selected FISH analysis to determine gene amplification in the clinical validation cohort.
Second, we defined a ERBB2 diagnostic algorithm, referred to as HERACLES Diagnostic Criteria. It focused on ERBB2 amplification, as preclinical data supporting the HERACLES trial suggested amplification and not only overexpression as the predictive marker for response to anti-ERBB2 treatment. 10 Within this algorithm, to minimize false positives owing to unspecific staining, we disregarded cytoplasmic ERBB2 expression, 19, 24 as in breast cancer only membrane-bound ERBB2 expression is associated with ERBB2 gene amplification. 19 As in breast cancer, in our colorectal cancer series, ERBB2 overexpression associated with gene amplification was also already clearly membrane bound at low magnification. Interestingly, normal colon mucosa was generally stained with higher intensity than both the normal ductal epithelium and the normal gastric epithelium (Supplementary Figure S2) . In breast and gastric cancer, the background staining noise can lead to reading biases, ultimately impinging on the concordance between ERBB2 immunohistochemistry and in situ hybridization. 25, 26 The presence of a moderately intense normal background might thus have contributed to the scoring of the false negative case observed also with the HercepTest in our test cohort. Normalization protocols to deal with this issue in breast cancer have been both suggested 25 and highly criticized. 27 No formal normalization protocol was used in the present study, but the normal mucosa reactivity was a factor constantly considered by the pathologist during the scoring process, and the main reason why centralized testing has been recommended.
Third, to have a better estimate of the number of patients needing to be screened in order to achieve the intended sample size, we determined the prevalence of ERBB2 amplification in a representative population from the catchment area of the planned trial. In our study, the prevalence rate for ERBB2 amplification in KRAS wild-type samples was almost identical, i.e., 5.1 vs 5.2% in the archival test and in the clinical screening cohorts, respectively, thus prospectively validating the Heracles Diagnostic Criteria. ERBB2 overexpression rates were also almost identical for positive (3+) cases (4.7 vs 4.0%), whereas equivocal scored (2+) cases halved from the test to the validation cohort (9.0 vs 4.5%, respectively), suggesting a learning curve by local and central pathologists.
ERBB2 overexpression and amplification rates in colorectal cancer range widely owing to differences in technical approaches, antibodies, scoring protocols, cellular localization, and cellularity cutoffs. [6] [7] [8] [9] [12] [13] [14] [15] [16] [17] [18] [19] [20] The present study is unique because the only study with an equally large sample size, albeit without clinical validation, reported much lower rates of both ERBB2 expression (2.7%) and positive amplification (1.6%). 8 This difference very likely resides in the fact that while our findings have been obtained on a primarily metastatic population, Heppner et al. 8 tested only primary tumors using a different staining antibody (SP3) and a different in situ hybridization method (CISH), and employed gastric cancer criteria to test and score the samples. Interestingly, the characteristics of ERBB2 positivity in our colorectal cancer samples are more similar to those of breast cancer than to gastric cancer. 3, 22, 28 ERBB2 staining in gastric cancer is not directly correlated to ERBB2 amplification, with up to 30% of ERBB2 amplification-positive cases showing only focal staining or diffuse staining in o 30% of tumor cells. 24 On the contrary, ERBB2 protein expression and gene amplification in our colorectal cancer samples tallied quite accurately. None of the ERBB2 expression-negative colorectal cancer was amplified, whereas all immunohistochemistry-positive colorectal cancers were, leaving only the equivocal staining tumors in a grey zone. In addition, the cellularity of ERBB2 amplification is quite homogeneous with all positive cases displaying the amplification in 450% of cells. Another key point is intra-sample heterogeneity. In gastric cancer, areas strongly expressing ERBB2 at low magnification are often intermixed with areas displaying a much weaker membranous signal, and are only discernible at medium or high magnification corresponding to superimposable areas of high and no or patchy amplification. 21 A similar pattern was only observed in 1 out of the 53 amplified cases in our colorectal cancer series, precisely in the one case showing also high heterogeneity between primary tumor and liver metastases samples. On the other hand, ERBB2 membrane distribution in equivocal staining colorectal cancer samples is preferentially basolateral (U shaped) as in gastric 21 but not in breast cancer. 4, 28 However, 470% of colorectacl cancer equivocal (2+) cases are not amplified and those that are amplified tend to show a slightly more patchwork-type intensity. Variability in the interpretation of immunohistochemistry staining and in situ hybridization results is to be expected in colorectal cancer, as testified by the still ongoing controversies on ERBB2 assessment in breast and gastric cancers, despite the continuous evolution of scoring guidelines. 21, 23, 29, 30 The crux of the matter, however, to ensure accurate identification of patients that might benefit from ERBB2-targeted therapy, across all tumor types, is whether the level of ERBB2 expression tallies or not with the level of ERBB2 amplification. In breast cancer, the level of ERBB2 protein is a known predictive factor of response to trastuzumab in metastatic disease 3 and of complete pathological response to the neoadjuvant therapy combination of lapatinib and trastuzumab. 31 Surprisingly, however, the level of amplification has been proven so far to be truly outcome predictive only for neoadjuvant therapy. [32] [33] [34] With gastric cancer in the ToGA trial, a trastuzumab-based regimen was found more effective in patients with tumors highly expressing the ERBB2 protein. 4 A positive correlation between levels of gene amplification and overall survival after trastuzumabbased therapy has also been recently established. 28 Early results from the HERACLES trial suggest that in colorectal cancer ERBB2 is a positive predictive marker for anti-ERBB2 targeted therapy. 35 In conclusion, in a series of 1086 colorectal cancers, we optimized a diagnostic decisional algorithm referred to as HERACLES Diagnostic Criteria for ERBB2 protein overexpression and documented that ERBB2 amplification occurs in 5% of the population.
This study is the first clinical step toward a paradigmatic precision medicine path, initiated by functionally validating ERBB2 as a therapeutic target in patient-derived xenografts from anti-EGFR therapyresistant, KRAS wild-type metastatic colorectal cancer patients. Data from this study have provided important information on the stratification criteria for the HERACLES trial, a phase II clinical trial testing the combination of trastuzumab and lapatinib in metastatic colorectal cancer patients resistant to cetuximab or panitumumab.
